President Trump’s Dec. 18 executive order fast‑tracks marijuana rescheduling, igniting industry excitement and legal scrutiny. The directive stops short of altering existing statutes that keep marijuana illegal to ship across state lines.
What the order actually does
President Trump’s Dec. 18 executive order directs Attorney General Pam Bondi to expedite marijuana’s move from Schedule I to Schedule III under the Controlled Substances Act, but it does not automatically rewrite federal drug policy or lift the ban on interstate cannabis transport.
Legal pathways and timelines
The Controlled Substances Act gives the president no unilateral power to reschedule; changes historically require either a formal rulemaking process or congressional legislation, according to Cannabis Regulators Association executive director Gillian Schauer. Such changes are historically achieved through a rulemaking process or congressional action.
Public comment and speed
Bondi may bypass a notice‑and‑comment period, shortening the timeline, though legal experts warn that anti‑marijuana groups are prepared to challenge the rule in court, potentially delaying final action. A notice‑and‑comment period could extend the timeline considerably.
Tax relief for dispensaries
Sam Brill, CEO of Ascend Wellness Holdings, says eliminating the 280E tax code would allow marijuana businesses to deduct normal expenses such as rent, payroll and interest, a change that could improve cash flow overnight. Brill says the windfall could let companies reinvest in growth and compliance.
Banking and payment constraints
Despite rescheduling, financial institutions still refuse credit‑card services to state‑licensed cannabis operators because of lingering federal liability concerns, leaving the industry cash‑dependent. The cash‑only model hampers customer convenience and weekly revenue tracking.
Research implications
Scientists welcome the removal of the Schedule I license requirement and eased laboratory regulations, but access to research‑grade marijuana remains limited to a few federally approved sources. The federal sourcing system still limits the variety of products available for study.
Expert caution
Gillian Schauer notes that headlines claiming immediate rescheduling and broad research breakthroughs are premature, emphasizing that agency guidance and legal challenges will shape the ultimate outcome. Schauer cautions that agency policy shifts will be needed to fully unlock research potential.
